• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»robotic surgery

Johnson & Johnson clears a key OTTAVA hurdle, but the harder robotics test comes next

By Pallavi Madhiraju on May 9, 2026   Medical Devices & Diagnostics  

Johnson & Johnson clears a key OTTAVA hurdle, but the harder robotics test comes next

Robotic surgery is opening up. Johnson & Johnson’s OTTAVA data may test whether hospitals want a new soft tissue platform.

Why Johnson & Johnson’s new ETHICON 4000 stapler could matter for European surgical workflow economics

By Pallavi Madhiraju on April 22, 2026   Medical Devices & Diagnostics  

Why Johnson & Johnson’s new ETHICON 4000 stapler could matter for European surgical workflow economics

Read how Johnson & Johnson’s ETHICON 4000 CE Mark approval could reshape surgical stapling, hospital economics, and future robotic integration.

What EndoQuest’s PARADIGM Trial approval reveals about robotic ESD innovation in GI surgery

By Pallavi Madhiraju on January 17, 2026   Medical Devices & Diagnostics  

What EndoQuest’s PARADIGM Trial approval reveals about robotic ESD innovation in GI surgery

EndoQuest wins FDA approval to complete PARADIGM Trial for its ELS system. Find out what this milestone means for robotic GI surgery innovation.

Vicarious Surgical bets on outsourced software execution to control costs and advance clinical timelines

By Pallavi Madhiraju on January 1, 2026   Medical Devices & Diagnostics  

Vicarious Surgical bets on outsourced software execution to control costs and advance clinical timelines

Vicarious Surgical shifts software development to a global partner to cut costs and hit clinical trial milestones. Here’s what this means for its platform.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes